Sumitomo Chemical Holds 9.0% Stake in Roivant Sciences

TL;DR

**Sumitomo Chemical still owns 9.0% of Roivant Sciences, showing continued institutional backing.**

AI Summary

Sumitomo Chemical Co., Ltd. filed an amended SC 13G/A on February 1, 2024, disclosing its beneficial ownership in Roivant Sciences Ltd. As of December 31, 2023, Sumitomo Chemical Co., Ltd. beneficially owns 71,251,083 common shares, representing 9.0% of Roivant Sciences Ltd.'s outstanding shares. This filing indicates a significant, but not controlling, stake by a major chemical company in a pharmaceutical firm, which could signal long-term strategic interest or a stable institutional holder for current and prospective investors.

Why It Matters

This filing confirms a substantial institutional investor's continued interest in Roivant Sciences, providing a degree of stability and potential strategic alignment for shareholders.

Risk Assessment

Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a floor for the stock.

Analyst Insight

Investors should note the continued significant institutional ownership by Sumitomo Chemical Co., Ltd., which suggests a stable long-term holder. This could be a positive signal for Roivant Sciences Ltd.'s stability, but does not imply immediate price action.

Key Numbers

• 71,251,083 — Common Shares Beneficially Owned (This is the total number of shares Sumitomo Chemical Co., Ltd. holds in Roivant Sciences Ltd.)
• 9.0% — Percentage of Class (This represents the proportion of Roivant Sciences Ltd.'s common shares beneficially owned by Sumitomo Chemical Co., Ltd.)
• December 31, 2023 — Date of Event (This is the effective date for the ownership reported in the filing.)
• $0.0000000341740141 — Par Value per Share (This is the stated par value of Roivant Sciences Ltd.'s common shares.)

Key Players & Entities

• Sumitomo Chemical Co., Ltd. (company) — the reporting person and beneficial owner
• Roivant Sciences Ltd. (company) — the subject company whose shares are being reported
• Japan (company) — place of organization for Sumitomo Chemical Co., Ltd.
• Sumitomo Pharma Co., Ltd. (company) — a group member mentioned in the filing

Forward-Looking Statements

• Sumitomo Chemical Co., Ltd. will maintain its significant stake in Roivant Sciences Ltd. for the foreseeable future. (Sumitomo Chemical Co., Ltd.) — medium confidence, target: December 31, 2024

FAQ

Key Financial Figures

• $0.0000000341740141 — e of Issuer) Common Shares, par value $0.0000000341740141 per share (Title of Class of Securiti

Filing Documents

• d724028dsc13ga.htm (SC 13G/A) — 49KB
• d724028dex991.htm (EX-99.1) — 4KB
• 0001193125-24-021952.txt ( ) — 54KB

(a)

Item 1(a). Name of Issuer: Roivant Sciences Ltd. (the Issuer).

(b)

Item 1(b). Address of Issuers Principal Executive Offices: Roivant Sciences Ltd. 7th Floor 50 Broadway London SW1H 0DB United Kingdom

(a)

Item 2(a). Name of Person Filing: Sumitomo Chemical Co., Ltd. (Sumitomo Chemical). Sumitomo Pharma Co., Ltd. (Sumitomo Pharma). (Each a Reporting Person, and collectively, the Reporting Persons).

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: Sumitomo Chemical: 7-1, Nihonbashi 2-chome Chuo-ku, Tokyo 103-6020, Japan Sumitomo Pharma: 6-8 Doshomachi 2-chome Chuo-ku, Osaka 541-0045, Japan

(c)

Item 2(c). Citizenship: See Row 4 of the cover page for each Reporting Person, respectively.

(d)

Item 2(d). Title of Class of Securities: Common Shares, par value $0.0000000341740141 per share of the Issuer (Common Shares).

(e)

Item 2(e). CUSIP Number: G76279101 Item 3. If this Statement is Filed Pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a: Not applicable. Item 4. (a) Amount beneficially owned: See Row 9 of the cover pages for each Reporting Person, respectively. (b) Percent of class: See Row 11 of the cover pages for each Reporting Person, respectively. Calculated using 803,921,356 Common Shares issued and outstanding as of November 9, 2023, as disclosed by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission on November 13, 2023. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: See Row 5 of the cover pages for each Reporting Person, respectively. (ii) Shared power to vote or to direct the vote: See Row 6 of the cover pages for each Reporting Person, respectively. (iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover pages for each Reporting Person, respectively. (iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover pages for each Reporting Person, respectively. Sumitomo Pharma directly owns the Common Shares. Sumitomo Pharma is a 51.76%-owned subsidiary of Sumitomo Chemical. Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the Common Shares that Sumitomo Pharma owns. Sumitomo Chemical disclaims beneficial ownership of such Common Shares except to the extent of its pecuniary interest therein. Item 5. Not applicable. Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. N

View Full Filing

View this SC 13G/A filing on SEC EDGAR